<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235013</url>
  </required_header>
  <id_info>
    <org_study_id>DIS-MVC</org_study_id>
    <nct_id>NCT01235013</nct_id>
  </id_info>
  <brief_title>Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3</brief_title>
  <acronym>DIS-MVC</acronym>
  <official_title>Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maraviroc is an antiretroviral drug that belongs to the family of the CCR5 coreceptor
      inhibitors. It has proven to be effective in increasing CD4 lymphocyte counts in both in
      treated and naïve patients, irrespective of the viral load.

      The investigators hypothesize that adding Maraviroc to the antiretroviral treatment of
      discordant patients, defined as those having CD4 lymphocyte counts below 200 cells /mm3
      during the last year, could lead to its immunological recovery.

      60 patients will be included in this unicentric, prospective, randomized and stratified
      clinical trial. They will be randomized to either continue with its usual high activity
      antiretroviral therapy (HAART) treatment or to receive 300 mg of Maraviroc every 12 hours
      plus its usual treatment. After 24 weeks, lymphocyte counts will be assessed, as well as
      safety, clinical progression, immunological profile of the patients and the potential benefit
      of Maraviroc for HIV+ cirrhotic patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median of CD4 counts change after 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological profile</measure>
    <time_frame>24 weeks</time_frame>
    <description>Immunohistochemistry and flow cytometry techniques will be performed on peripheral blood to study immunological response to Maraviroc treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 counts</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of pacients with CD4 counts over 200 cells/mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression</measure>
    <time_frame>24 weeks</time_frame>
    <description>Progression to diseases classified as category C in CDC HIV guidelines; to other diseases or patient death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients continue with their usual treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks</description>
    <arm_group_label>Maraviroc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  HIV infection

          -  Patients receiving HAART treatment for at least one year with a sustained viral load
             equal or below 200 copies/ml

          -  Viral load equal or below 200 copies/ml at the screening visit

          -  Discordant patients: patients without an increment over 50 copies /ml of CD4
             lymphocytes during the last year

          -  Patients with an expected adherence to HIV treatment over 90% according to their
             physician.

          -  Signed informed consent form

        Exclusion Criteria:

          -  Pregnancy or breast feeding or women planning pregnancy during the study duration

          -  Any contraindication to treatment with Maraviroc

          -  X4 tropism at inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Luis Blanco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José María Gatell, MD</last_name>
    <phone>0034932275400</phone>
    <email>jmgatell@clinic.ub.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judit Pich, Pharmacist</last_name>
    <phone>0034932275400</phone>
    <email>jpich@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José María Gatell, MD</last_name>
      <phone>0034932275400</phone>
      <email>jmgatell@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Judit Pich, Pharmacist</last_name>
      <phone>0034932275400</phone>
      <email>jpich@clinic.ub.es</email>
    </contact_backup>
    <investigator>
      <last_name>José Luis Blanco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <last_update_submitted>November 18, 2010</last_update_submitted>
  <last_update_submitted_qc>November 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. José María Gatell</name_title>
    <organization>Hospital Clínic i Provincial de Barcelona</organization>
  </responsible_party>
  <keyword>HIV-1 infection</keyword>
  <keyword>Maraviroc</keyword>
  <keyword>CD4 lymphocyte count</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

